Evidence map›Paper›PMID 25270058›Full record

ArticleJournal of chromatography. B, Analytical technologies in the biomedical and life sciences2014

Protein solubilization: a novel approach.

David H Johnson, W William Wilson, Lawrence J DeLucas

Abstract read
In one paragraph

Article in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Improving the solubility of single domain antibodies using VH-like hallmark residues.Protein science : a publication of the Protein Society · 2025
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

David H JohnsonDepartment of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, USA.
W William WilsonDepartment of Chemistry, Mississippi State University, Starkville, MS, USA.
Lawrence J DeLucasCenter for Biophysical Sciences and Engineering, University of Alabama at Birmingham, 1530 Third Avenue South, Birmingham, AL 35294, USA. Electronic address: delucas@cbse.uab.edu.

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
Production & Crystallization of Membrane Protein for 3D StructureR01GM095639 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DELUCAS, LAWRENCE J · 2010 to 2013
$1.2M
NCI NIH HHS 5P30CA13148-40NCI NIH HHS P30 CA013148NIGMS NIH HHS R01 GM095639NIGMS NIH HHS R01GM095639
6 · The paper itself

Abstract

Formulation development presents significant challenges with respect to protein therapeutics. One component of these challenges is to attain high protein solubility (>50mg/ml for immunoglobulins) with minimal aggregation. Protein-protein interactions contribute to aggregation and the integral sum of these interactions can be quantified by a thermodynamic parameter known as the osmotic second virial coefficient (B-value). The method presented here utilizes high-throughput measurement of B-values to identify the influence of additives on protein-protein interactions. The experiment design uses three tiers of screens to arrive at final solution conditions that improve protein solubility. The first screen identifies individual additives that reduce protein interactions. A second set of B-values are then measured for different combinations of these additives via an incomplete factorial screen. Results from the incomplete factorial screen are used to train an artificial neural network (ANN). The "trained" ANN enables predictions of B-values for more than 4000 formulations that include additive combinations not previously experimentally measured. Validation steps are incorporated throughout the screening process to ensure that (1) the protein's thermal and aggregation stability characteristics are not reduced and (2) the artificial neural network predictive model is accurate. The ability of this approach to reduce aggregation and increase solubility is demonstrated using an IgG protein supplied by Minerva Biotechnologies, Inc.

Indexed as

Chemistry, PharmaceuticalChromatographyDrug IndustryDrug InteractionsDrug StabilityNeural Networks, ComputerProteinsSolubilitySolutionsThermodynamicsProteinsSolutionsDesign of experimentsHigh-throughput screeningNeural networkPhysical stabilityProtein solubilitySelf-interaction chromatography

Identifiers

PMID25270058
PMCPMC4254358

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.